Bausch Health Companies Inc

Bausch Health Cos., Inc. engages in the development, manufacture and market of a range of branded, generic and branded generic pharmaceuticals, medical devices and over-the-counter products. It operates through the following segments: The Bausch + Lomb/International, Salix, Ortho Dermatologics and Diversified Products. The Bausch + Lomb/International segment consists of the sale of pharmaceutical products, over-the-counter products, and medical devices products. The Salix segment consists of sales in the U.S. of GI products. The Ortho Dermatologics segment consists of sales in the U.S. of Ortho Dermatologics (dermatological) products and global sales of Solta medical aesthetic devices. The Diversified Products segment consists of sales in the U.S. of pharmaceutical products in the areas of neurology and certain other therapeutic classes, in the U.S. of generic products, in the U.S. of dentistry products. The company was founded on March 29, 1994 and is headquartered in Laval, Canada.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Bausch Health Cos., Inc. engages in the development, manufacture and market of a range of branded, generic and branded generic pharmaceuticals, medical devices and over-the-counter products. It operates through the following segments: Salix, International, Solta Medical, Diversified Products, and Bausch + Lomb. The Salix segment consists of sales in the U.S. of GI products. Sales of the Xifaxan product line. The International segment comprises of sales, except for sales of Bausch + Lomb products and Solta aesthetic medical devices, outside the U.S and Puerto Rico of branded pharmaceutical products, branded generic pharmaceutical and OTC products. The Solta Medical segment refers to global sales of Solta Medical aesthetic medical devices. The Diversified Products segment covers sales in the U.S. of pharmaceutical products in the areas of neurology and certain other therapeutic classes, generic products, ortho dermatologic, and dentistry products. The Bausch + Lomb segment are global sales of Bausch + Lomb vision care, surgical and ophthalmic pharmaceuticals products. The company was founded on March 29, 1994, and is headquartered in Laval, Canada.

Bausch's (BHC) amiselimod achieves the primary and key secondary endpoints, including clinical and endoscopic measures, in the double-blind period of a phase II study.

Bausch Health (BHC) Ulcerative Colitis Drug Meets Primary Goal

Trial Meets Both Primary and Key Secondary Endpoints LAVAL, QC / ACCESSWIRE / December 21, 2023 / Bausch Health Companies Inc. (NYSE:BHC)(TSX:BHC) ("Bausch Health" or the "Company") today announced positive topline results from the Company's Phase 2 study evaluating Amiselimod, an investigative S1P antagonist, for the treatment of ulcerative colitis (UC). "We are thrilled with these impressive topline results, and believe that this could offer a much needed improvement in therapy available for patients with ulcerative colitis," said Thomas J.

Bausch Health Announces Positive Topline Results From Global Phase 2 Study Evaluating Amiselimod (an S1P antagonist) to Treat Ulcerative Colitis

LAVAL, QC / ACCESSWIRE / December 18, 2023 / Bausch Health, Canada, part of Bausch Health Companies Inc. (NYSE:BHC)(TSX:BHC), ("Bausch Health" or the "Company") today announced that DUOBRII™ (0.01% w/w halobetasol propionate and 0.045% w/w tazarotene), the company's novel topical prescription drug for improving the signs and symptoms of plaque psoriasis in adult patients with moderate to severe disease,1 is now available to patients enrolled in Quebec's public drug plan operated by the Régie de l'assurance maladie du Québec (RAMQ). DUOBRII is already available as a benefit on most other public drug plans in the rest of Canada, including the federal government's Non-Insured Health Benefits (NIHB) program, as well as most private drug insurance plans.

DUOBRII(TM) Lotion to Treat Moderate to Severe Plaque Psoriasis Now Available Through Quebec's Public Drug Plan

The mean of analysts' price targets for Bausch (BHC) points to a 30.1% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.

Wall Street Analysts Think Bausch (BHC) Could Surge 30.14%: Read This Before Placing a Bet

Subaru Corp

Haleon PLC

Known for historically being the strongest month of the year for U.S. stocks, the Dow and S&P 500 both gained nearly 9% last month. The Nasdaq, almost 11%.

3 cheap 'stock'-ing stuffers Wall Street is bullish on

BRIDGEWATER, NJ / ACCESSWIRE / December 5, 2023 / Salix Pharmaceuticals, the gastroenterology division of Bausch Health Companies Inc. (NYSE:BHC)(TSX:BHC), The U.S. Pain Foundation (USPF), and The International Foundation for Gastrointestinal Disorders (IFFGD) today announced they are joining forces to declare Tuesday, Dec. 5, Opioid-Induced Constipation (OIC) Awareness Day. OIC Awareness Day aims to bring awareness to an often-overlooked side effect of opioids.

Salix in Collaboration with The U.S. Pain Foundation and the International Foundation for Gastrointestinal Disorders Establish the Inaugural Opioid-Induced Constipation (OIC) Awareness Day

Here is how Bausch Health (BHC) and Gracell Biotechnologies Inc. Sponsored ADR (GRCL) have performed compared to their sector so far this year.

Is Bausch Health (BHC) Stock Outpacing Its Medical Peers This Year?

The average of price targets set by Wall Street analysts indicates a potential upside of 38.3% in Bausch (BHC). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.

Wall Street Analysts Believe Bausch (BHC) Could Rally 38.28%: Here's is How to Trade

VAUGHAN, Ontario--(BUSINESS WIRE)--Bausch + Lomb Corporation (NYSE/TSX: BLCO), a leading global eye health company dedicated to helping people see better to live better, today announced its exclusive ONE by ONE and Biotrue Eye Care Recycling programs have collected a total of 76,645,000 million units, or 464,100 pounds, of used contact lenses, eye care and lens care materials in the United States, which is equivalent to the weight of 140 hippos1. “As a result of the contributions of eye care pr.

Bausch + Lomb Reports More Than 76 Million Units of Contact Lenses, Lens Care and Eye Care Materials Collected Through ONE By ONE and Biotrue® Eye Care Recycling Programs

Bausch (BHC) witnesses a hammer chart pattern, indicating support found by the stock after losing some value lately. This coupled with an upward trend in earnings estimate revisions could mean a trend reversal for the stock in the near term.

Bausch (BHC) May Find a Bottom Soon, Here's Why You Should Buy the Stock Now

Lack of OHE-specific diagnostic code in hospitals may increase risk of additional cost, length of hospitalization and additional burdens for patients compared to those with a previous primary OHE diagnosis LAVAL, QC / ACCESSWIRE / November 10, 2023 / Bausch Health Companies Inc. (NYSE:BHC)(TSX:BHC) and its gastroenterology business, Salix Pharmaceuticals, today announced findings from a descriptive analysis of a hospital database (October 2015-June 2022) showing that the absence of an overt hepatic encephalopathy-specific diagnosis code may have resulted in increased OHE-related length of stay (LOS) and hospitalization-related costs due to OHE rate underestimation. The analysis of hospital data showed that OHE hospitalizations identified using in-hospital Xifaxan® (rifaximin) or lactulose use combined with a diagnosis for altered mental status, unspecified encephalopathy, or cirrhosis, had a mean hospital billing charge 2.5 times higher and mean length of stay (LOS) 2.0 times longer than solely relying on OHE as a primary diagnosis.

The Absence of an Overt Hepatic Encephalopathy (OHE)-Specific Diagnosis Code May Result in Increased OHE-Related Length of Stay and Hospitalization-Related Costs Due to OHE Rate Underestimation, According to New Analysis

Bausch (BHC) surpasses third-quarter earnings and sales estimates as most of the business units post growth.

Bausch Health (BHC) Q3 Earnings & Sales Beat, '23 View Updated

The headline numbers for Bausch (BHC) give insight into how the company performed in the quarter ended September 2023, but it may be worthwhile to compare some of its key metrics to Wall Street estimates and the year-ago actuals.

Bausch (BHC) Q3 Earnings: How Key Metrics Compare to Wall Street Estimates

Bausch Health Companies Inc. (NYSE:BHC ) Q3 2023 Earnings Conference Call November 2, 2023 8:00 AM ET Company Participants Lisa Wilson - Investor Relations Thomas Appio - Chief Executive Officer John Barresi - Interim Chief Financial Officer Conference Call Participants Jason Gerberry - Bank of America Securities Umer Raffat - Evercore ISI David Amsellem - Piper Sandler Douglas Miehm - RBC Capital Markets Les Sulewski - Truist Securities Operator Greetings. Welcome to the Bausch Health Third Quarter 2023 Earnings Call.

Bausch Health Companies Inc. (BHC) Q3 2023 Earnings Call Transcript

Revenue of $2.24 billion, up 9% on both a Reported and Organic1 basis Year-over-year revenue growth in all segments on both a Reported and Organic Basis GAAP Net Loss Attributable to Bausch Health Companies Inc. of $378 Million Adjusted EBITDA Attributable to Bausch Health Companies Inc. (non-GAAP)1 of $830 Million, up 8% Provides updated full-year Revenue and Adjusted EBITDA (non-GAAP)1 guidance Received U.S. Food and Drug Administration ("FDA") approval for CABTREOTM (IDP-126), the first and only FDA-approved fixed-dose, triple-combination topical treatment for acne LAVAL, QC / ACCESSWIRE / November 2, 2023 / Bausch Health Companies Inc. (NYSE:BHC)(TSX:BHC) ("Bausch Health" or the "Company" or "we" or "our") today announced its third-quarter 2023 financial results and other key updates from the quarter. "We are pleased with our solid third-quarter performance, as each of our business segments posted year-over-year revenue growth on both a reported and organic basis.

Bausch Health Announces Third-Quarter 2023 Results

LAVAL, QC / ACCESSWIRE / November 1, 2023 / Bausch Health Companies Inc. (NYSE:BHC)(TSX:BHC), and its gastroenterology business Salix Pharmaceuticals, Inc., today announced that the U.S. District Court for the District of Columbia in the matter of Norwich Pharmaceuticals, Inc. v. Becerra, et al.

U.S. District Court Dismisses Norwich's Lawsuit Against the FDA

Contact lens maker Bausch + Lomb Corporation reported third-quarter earnings that surpassed Wall Street projections, even as the company posted an $84 million loss. On an adjusted basis, accounting for amortization and pretax expenses, the company earned 22 cents per share, beating the average analyst estimate of 18 cents per share.

Bausch + Lomb shares up 3.2% after contact lens maker beats the Street

VAUGHAN, Ontario--(BUSINESS WIRE)--Bausch + Lomb Corporation (NYSE/TSX: BLCO), a leading global eye health company dedicated to helping people see better to live better, today announced its third-quarter 2023 financial results. “We continue to grow revenue at or above market thanks to the strength of established and emerging brands that cover the entire spectrum of eye health,” said Brent Saunders, chairman and CEO, Bausch + Lomb. “Our multi-year effort to rewire the company is gaining traction.

Bausch + Lomb Announces Third-Quarter 2023 Results and Raises Full-Year 2023 Guidance

First-Ever Television Ad Campaign for APLENZIN® (bupropion hydrobromide) Airs in October LAVAL, QC / ACCESSWIRE / October 26, 2023 / Bausch Health Companies Inc. (NYSE:BHC)(TSX:BHC) today announced the new release of "Looking Forward," the television ad campaign for APLENZIN® (bupropion hydrobromide) extended-release tablets for individuals diagnosed with seasonal affective disorder (SAD), a type of depression that follows a seasonal pattern. This represents the first-ever television commercial for a prescription medication indicated for the prevention of autumn-winter SAD.

Bausch Health Unveils "Looking Forward" - A New DTC Television Campaign for Seasonal Affective Disorder (SAD)

VAUGHAN, Ontario--(BUSINESS WIRE)--Bausch + Lomb Corporation (NYSE/TSX: BLCO), a leading global eye health company dedicated to helping people see better to live better, today announced three podium presentations and seven poster presentations during the American Academy of Ophthalmology (AAO) annual meeting, which will take place in San Francisco Nov. 3-6, 2023. Three podium presentations will feature an evaluation of the use of IC-8 Apthera intraocular lens (IOL) in patients with complex case.

Bausch + Lomb Will Present New Scientific Data and Analyses at American Academy of Ophthalmology Annual Meeting

First and only FDA-approved fixed-dose, triple-combination topical treatment LAVAL, QC / ACCESSWIRE / October 20, 2023 / Bausch Health Companies Inc. (NYSE:BHC) (TSX:BHC) ("Bausch Health") and its dermatology business, Ortho Dermatologics, today announced that the U.S. Food and Drug Administration (FDA) has approved the New Drug Application for CABTREOTM (clindamycin phosphate, adapalene and benzoyl peroxide) Topical Gel 1.2%/0.15%/3.1%, indicated for the topical treatment of acne vulgaris in patients twelve years of age and older. CABTREO is the first and only FDA-approved fixed-dose, triple-combination topical treatment for acne.

FDA Approves Cabtreo(TM) (Clindamycin Phosphate, Adapalene and Benzoyl Peroxide) Topical Gel for the Treatment of Acne Vulgaris in Patients Twelve Years of Age and Older

Hurdles Led to Almost All Patients Having At Least One Day Delay to Receive Treatment with Xifaxan® LAVAL, QC / ACCESSWIRE / October 17, 2023 / Bausch Health Companies Inc. (NYSE:BHC)(TSX:BHC) and its gastroenterology business, Salix Pharmaceuticals, today announced findings from a retrospective database analysis of adjudicated claims data that examined the impact of access barriers for commercially-insured adults prescribed Xifaxan® (rifaximin) for reduction in risk of overt hepatic encephalopathy (OHE) recurrence in adults. Results suggest potentially critical treatment gaps due to access barriers, which may result in increased rates of OHE-related hospitalizations.

New Analysis Indicates That a Majority of Overt Hepatic Encephalopathy (OHE) Patients May Face Delays in Treatment Initiation and Gaps During Treatment for Access to Treatment Indicated to Reduce Risk for OHE Recurrence

VAUGHAN, Ontario--(BUSINESS WIRE)--Bausch + Lomb Corporation (NYSE/TSX: BLCO), a leading global eye health company dedicated to helping people see better to live better, will release its third-quarter 2023 financial results on Wednesday, Nov. 1, 2023. Bausch + Lomb will host a conference call and live webcast at 8 a.m. ET to discuss the results and provide a business update. All materials will be made available on the Investor Relations section of the Bausch + Lomb website prior to the start of.

Bausch + Lomb Will Release Third-Quarter 2023 Financial Results on November 1

LAVAL, QC / ACCESSWIRE / October 12, 2023 / Bausch Health Companies Inc. (NYSE:BHC)(TSX:BHC) will release its third-quarter financial results on Thursday, Nov. 2, 2023. Bausch Health will host a conference call and live webcast at 8:00 a.m.

Bausch Health to Announce Third-Quarter 2023 Results on Nov. 2

Salix Pharmaceuticals' Liver Health Annual Trends Report Findings Suggest Chronic Liver Disease (CLD) Deaths Could Triple Before the End of the Decade Based Primarily on HCP-Market Research, Report Finds a Growing Concern of Staffing Shortages Across Multiple Healthcare Professions that Treat Liver Disease LAVAL, QC / ACCESSWIRE / October 10, 2023 / Salix Pharmaceuticals, the gastroenterology business of Bausch Health Companies Inc. (NYSE:BHC)(TSX:BHC), today released the Salix Liver Health Trends Report, Third Edition, which documents the evolving crisis of chronic liver disease (CLD), showing a 9% increase in CLD and cirrhosis mortality marking these as the ninth leading cause of death in the United States in 2021. The report, based on a survey of 400 health care providers (HCPs) who treat CLD, qualitative interviews with HCPs and secondary research from peer-reviewed publications, also stresses the ongoing disparities and gaps in CLD care that affect different populations and geographies, including a shortage of liver specialists in rural areas.

Salix Pharmaceuticals Releases Liver Health Annual Trends Report Identifying Increase in Chronic Liver Disease and Cirrhosis-Related Deaths Marking These as Ninth Leading Cause of Death in U.S.

News for Bausch Health Companies Inc Stock (BHC)